The Drug Enforcement Administration opened an application portal on April 29 for state-licensed medical cannabis dispensaries seeking expedited Schedule III registration - a direct consequence of Acting Attorney General Todd Blanche's April 23 order rescheduling medical cannabis under the Controlled Substances Act. For the first time in decades of federal prohibition, operators have a formal pathway to federal recognition. The catch is that walking through it requires answering questions that could expose them to significant legal liability.
The Rescheduling Order and What It Actually Offers
Blanche's order invokes U.S. treaty obligations under the United Nations Single Convention on Narcotic Drugs to move FDA-approved cannabis products and state-licensed medical cannabis from Schedule I - a category historically reserved for substances deemed to have no accepted medical use - to Schedule III. The practical implications are not trivial. Schedule III status removes a business from the grip of Section 280E of the Internal Revenue Code, which has long barred cannabis companies from deducting ordinary business expenses on federal taxes. That alone represents a substantial financial shift for any operator running a margin-sensitive retail or cultivation operation.
Beyond tax treatment, DEA registration as a Schedule III entity opens doors that have been categorically shut: potential access to export licenses, a cleaner path through banking compliance, eligibility for exchange listings, and a more legible legal posture for mergers and acquisitions. If interstate commerce eventually becomes federally permissible - still a significant "if" - registered businesses would have a documented compliance record from which to operate. These aren't hypothetical benefits. They are structural advantages that reshape how a cannabis company is valued and financed.
Operators who apply by June 26 qualify for expedited review, with the federal government committed to issuing a decision within six months. Those who miss that window get no such guarantee - and no clarity from the rescheduling order on when a second round of applications might open. That ambiguity is doing real work here, pushing businesses toward a decision they might otherwise take more time to consider.
The Liability Problem Hidden Inside the Application
Here's the thing: the application form includes five liability questions, and at least two of them put honest applicants in an uncomfortable position.
One asks whether anyone involved in the ownership or operation of the firm has previously manufactured, distributed, or dispensed a controlled substance without a DEA registration. For virtually every state-licensed cannabis business in the country, the answer is yes - because DEA registration wasn't available to them until now. Cannabis has been a Schedule I controlled substance under federal law since 1970. Operating a dispensary in Colorado or a cultivation facility in California has always meant handling a federally prohibited substance without federal authorization, regardless of state licensing. Applicants who answer yes must identify the individuals involved and provide an explanation.
The second difficult question appears under the activity section: will the firm be handling or dispensing recreational marijuana? Answering yes is, functionally, an admission to the federal government of involvement in trafficking a Schedule I controlled substance - because adult-use cannabis remains exactly that until a broader rescheduling rule is finalized. That broader administrative hearing, announced in a separate Blanche order, is scheduled to commence June 29 and must conclude by July 15, 2026. Operators applying for expedited registration will submit their forms before knowing the outcome of that process.
Cannabis Business Times submitted questions to the DEA seeking clarification on whether a "yes" answer to the prior-activity question would hinder, help, or simply have no effect on an application's outcome. No guidance has been forthcoming. That silence is itself informative - the DEA is not in the business of counseling applicants through legally sensitive disclosures. The application's closing warning is blunt: intentionally furnishing false information carries penalties of up to four years in prison, a $250,000 fine, or both.
Who's Moving First - and What That Signals
Florida-based multistate operator Trulieve didn't wait. The company, which runs more than 200 medical-only dispensaries and derives roughly 85% of its nationwide store count from medical cannabis operations, filed its DEA registration applications the same afternoon the portal opened. CEO Kim Rivers characterized the filing as "a historic step forward." That framing is deliberate - Trulieve operates almost entirely in medical markets, meaning its exposure to the recreational-marijuana liability question is minimal compared to operators running dual-use facilities in states like California, Michigan, or Illinois.
For multistate operators with mixed medical and adult-use portfolios, the calculus is more fraught. Registering as a Schedule III medical cannabis business while simultaneously running adult-use sales under the same corporate umbrella requires careful structural separation - and probably a substantial legal bill before anyone touches the submit button. Attorneys at Harris Sliwoski have estimated application preparation costs at $10,000 to $15,000 per engagement, with additional fees depending on the number and complexity of registrations involved. The potential upside, they note, runs into the hundreds of thousands or millions of dollars for well-positioned operators.
To put it plainly: this is a risk-weighted decision, not a straightforward compliance exercise. Businesses with clean medical-only footprints have the clearest path. Everyone else is doing more complicated math.
The Deeper Problem: Decades of Federal Distrust Don't Dissolve Overnight
Federal prohibition of cannabis began in earnest with the Controlled Substances Act of 1970, though restrictions predated that statute significantly. For more than fifty years, state-licensed operators built businesses in deliberate legal isolation from federal oversight - because federal oversight meant criminal exposure, not regulatory partnership. Banking institutions refused accounts. Insurance carriers hedged. Capital markets stayed at arm's length. The entire infrastructure of cannabis commerce developed in workarounds: cash-heavy operations, complex corporate structures, state-only licensing regimes with no federal analog.
What the Trump administration is now offering - accelerated registration, Schedule III status, potential tax relief - is, in historical terms, a significant policy shift. But it arrives wrapped in forms that ask operators to enumerate their prior federal violations, with a $794 nonrefundable fee and no guarantee of approval. The DEA retains authority to deny registration on public-interest grounds under 21 U.S.C. 823. The attorney general retains authority to revoke it. And the rescheduling of adult-use cannabis remains unresolved, dependent on a hearing process that won't conclude for over a year.
Skepticism, under these conditions, is not paranoia. It's institutional memory. The operators who built this industry did so despite federal law, not with its blessing. Whether a portal opened in April 2025 is enough to change that calculus - for most businesses, the answer will depend less on ideology than on legal exposure, operational structure, and how much risk their balance sheets can absorb.
